<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Treatment and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Treatment and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Treatment and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eoin P Flanagan, MB.BCh
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jan-Mendelt Tillema, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Francisco González-Scarano, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H523213724">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory disorder of the central nervous system characterized by attacks of immune-mediated demyelination predominantly targeting the optic nerves, brain, and spinal cord. The disease has a predilection for children.
        </p>
        <p>
         The treatment and prognosis of MOGAD are reviewed here. Other clinical aspects of MOGAD are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">
          "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1334649244">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of MOGAD can be stratified by acute attack treatment and attack prevention strategies.
        </p>
        <p class="headingAnchor" id="H1629664375">
         <span class="h2">
          Treatment of acute attacks
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since acute attacks of MOGAD tend to be severe, almost all are treated. Starting acute treatment as quickly as possible is a good strategy, as there is some evidence suggesting that early treatment of acute attacks with glucocorticoids may prevent residual damage [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-dose glucocorticoids
         </strong>
         – We suggest initial treatment with high-dose intravenous (IV)
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (1000 mg in adults, or 20 to 30 mg/kg per day in children) for five consecutive days. This agrees with expert panel recommendations and is based upon studies of multiple sclerosis (MS) and idiopathic optic neuritis. (See
         <a class="medical medical_review" href="/z/d/html/1698.html" rel="external">
          "Treatment of acute exacerbations of multiple sclerosis in adults", section on 'Initial therapy with glucocorticoids'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5252.html" rel="external">
          "Optic neuritis: Prognosis and treatment", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         With increasing evidence of a similar effectiveness of oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         in adults at the equivalent dose of 1250 mg once daily (25 tablets daily of oral prednisone 50 mg tablets) for five days, we also consider that as an alternative to the 1 gram IV
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         infusion for treatment of acute attacks in adults [
         <a href="#rid2">
          2
         </a>
         ]. Such studies have not been performed in children.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In general, MOGAD tends to be quite responsive to glucocorticoid therapy, with rapid reversal of symptoms in most cases [
         <a href="#rid3">
          3
         </a>
         ]; this can at times even serve as a diagnostic clue. In one report with data available for 122 attacks treated with IV
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         , outcomes included complete or almost complete recovery in 50 percent, partial recovery in 44 percent, and no or almost no recovery in 6 percent [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Utility of glucocorticoid slow taper
         </strong>
         – Some experts have reported a slow oral glucocorticoid taper over a few months may reduce the risk of early relapse [
         <a href="#rid3">
          3,5
         </a>
         ]. We commonly utilize this approach in adults and children after their first attack and sometimes with recurrent attacks; a slow glucocorticoid taper may be helpful in patients with relapsing disease who are starting maintenance attack-prevention immunotherapy, which often requires weeks to months to take effect. However, further study of the benefits and risks of this strategy are needed, particularly for patients with frequent relapses, as prolonged oral glucocorticoid treatment has a high potential adverse effect burden.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H810597554">
         <span class="h2">
          Failure of initial acute therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with MOGAD who are refractory to initial acute therapy with glucocorticoids or have an incomplete response, we suggest therapeutic plasma exchange. This was shown to be efficacious in a randomized trial (published in 1999) of patients with central nervous system (CNS) inflammatory demyelinating disease who were refractory to IV glucocorticoids, although the trial was done before myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) testing was available [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Plasma exchange treatment is usually administered as one exchange every other day for five to seven exchanges in total [
         <a href="#rid6">
          6
         </a>
         ]. The ability to administer this procedure in younger children and its tolerability depends on the expertise of the treating center. (See
         <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1864.html" rel="external">
          "Therapeutic plasma exchange (plasmapheresis) with hemodialysis equipment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7942.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Complications"
         </a>
         .)
        </p>
        <p>
         Intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) is an alternative, particularly in children with MOGAD, and is administered as a total dose of 2 g/kg divided over two to five days [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">
          "Intravenous immune globulin: Adverse effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1214396140">
         <span class="h2">
          Approach to attack prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rationale for preventive treatment of MOGAD is that mild attack-related disability accumulates with each attack  (
         <a class="graphic graphic_figure graphicRef131864" href="/z/d/graphic/131864.html" rel="external">
          figure 1
         </a>
         ), and attacks can be severe and debilitating when they occur [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H267815285">
         <span class="h3">
          Following the initial attack
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since up to 50 percent of patients may have a monophasic course, empiric immunosuppression is generally reserved for those who have relapsing disease. This approach avoids exposure to immunosuppression and its attendant risks for patients who may not relapse. At this stage, persistence of antibody titers at follow-up does not aid such a decision, which should be made on clinical grounds. On rare occasions, empiric immunosuppression has been utilized after the first attack when there is a severe residual deficit (eg, if the initial attack was devastating and led to blindness in one or both eyes or permanent paralysis and inability to ambulate). There are no evidence-based data for this approach.
        </p>
        <p class="headingAnchor" id="H956526750">
         <span class="h3">
          Relapsing disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted, attack prevention treatments are generally restricted to those who have relapsing disease. Options for therapy include
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil, intermittent
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , or
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         , as described in more detail below. The treatment approach has been extrapolated from experience with other neurologic autoimmune diseases such as aquaporin-4 positive IgG (AQP4-IgG) neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis. There have been no randomized controlled trials of preventive treatment for MOGAD, and thus evidence to support the use of attack prevention immunosuppression is based on expert opinion, case reports, and other retrospective observational data.
        </p>
        <p>
         Limited observational evidence suggests that treatment of MOGAD with some disease-modifying treatments aimed at MS is ineffective, including beta-interferon,
         <a class="drug drug_general" data-topicid="88899" href="/z/d/drug information/88899.html" rel="external">
          dimethyl fumarate
         </a>
         ,
         <a class="drug drug_general" data-topicid="16078" href="/z/d/drug information/16078.html" rel="external">
          fingolimod
         </a>
         ,
         <a class="drug drug_general" data-topicid="8490" href="/z/d/drug information/8490.html" rel="external">
          glatiramer acetate
         </a>
         ,
         <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">
          natalizumab
         </a>
         , and
         <a class="drug drug_general" data-topicid="86616" href="/z/d/drug information/86616.html" rel="external">
          teriflunomide
         </a>
         [
         <a href="#rid4">
          4,9-11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3430065442">
         <span class="h4">
          Oral immunosuppressants
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          Azathioprine
         </a>
         and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil are the most commonly prescribed oral glucocorticoid-sparing immunosuppressant medications for MOGAD. They often require transitional glucocorticoid treatment for three to six months, as they take this amount of time to take effect.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Azathioprine
         </strong>
         –
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          Azathioprine
         </a>
         prevents B and T cell proliferation by preventing purines from being synthesized through
         <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">
          6-mercaptopurine
         </a>
         . It is typically dosed at 2 to 3 mg/kg in single or divided doses by mouth daily. Assessing thiopurine-S-methyltransferase enzyme activity is important prior to starting, as low activity increases the risk of side effects and may warrant lower dosing or consideration of alternatives. In retrospective observational studies, azathioprine treatment has been associated with reduced annualized relapse rates [
         <a href="#rid4">
          4,5,9,10,12
         </a>
         ]. Up to 50 percent of patients may still have relapses despite this treatment, although some relapses may have occurred within the first six months before the medicine had taken effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adverse effects include infection, rash, cytopenias, elevated liver enzymes, and potential risk in the long-term of malignancy (lymphoma or skin cancers), and regular monitoring of complete blood count and kidney and liver function is required initially prior to use and thereafter is recommended.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycophenolate
         </strong>
         <strong>
         </strong>
         –
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          Mycophenolate
         </a>
         is an oral immunosuppressant that inhibits inosine monophosphate dehydrogenase, which is important for guanosine nucleotide production and thus prevents B and T cell proliferation. The dose in adults is typically 500 mg twice daily for two weeks and then increases to a maintenance dose of 1000 mg twice daily. In children, the goal dose is 650 mg/m
         <sup>
          2
         </sup>
         per day given in two divided doses (maximum 1000 mg twice daily). Mycophenolate treatment of MOGAD was associated with a reduction of annualized relapse rates in retrospective observational studies [
         <a href="#rid5">
          5,9-11
         </a>
         ]. Similar to
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , relapses may still occur in 50 percent, but early relapse may be secondary to the delayed onset of action of mycophenolate treatment, which is generally three to six months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Gastrointestinal disorders are the most common adverse effects with
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , and there is an increased risk of malignancy with long-term treatment. Mycophenolate is also teratogenic in females. It is associated with an increased risk of infection, and cytopenia may occur. Thus, regular monitoring of complete blood count prior to use and thereafter is recommended. Kidney and liver function should also be assessed prior to its use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prednisone
         </strong>
         – Oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         has broad immunosuppressive effects, including reducing cytokines and promoting an anti-inflammatory environment. It has been used at doses of up to 1 mg/kg per day followed by a taper. Prednisone treatment of MOGAD is associated with a reduced relapse risk, but use is limited by its poor tolerability and adverse effect profile with long-term therapy [
         <a href="#rid5">
          5,9,12
         </a>
         ]. Thus, its use is generally temporary to prevent early relapse or to give protection while other medications take effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adverse effects include infection (particularly pneumocystis jiroveci pneumonia), cushingoid appearance, skin thinning, bruising, insomnia, psychosis, depression, cataracts, hypertension, weight gain, peripheral edema, avascular necrosis of the hip, and risk of Addisonian crisis when discontinuing abruptly. The impact on bone health with risks of osteoporosis and risk of growth retardation are especially problematic in children that are particularly predisposed to MOGAD. Calcium and vitamin D to reduce the risk of osteoporosis and prophylactic antibiotics against pneumocystis jiroveci are needed in those on ≥20 mg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         per day and additional immunosuppressant medications or who have another cause of immunocompromise. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2032.html" rel="external">
          "Clinical features and evaluation of glucocorticoid-induced osteoporosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1615174123">
         <span class="h4">
          Infusion medications
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous
         </strong>
         <strong>
          immune globulin
         </strong>
         –
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         maintenance infusions have been used to prevent attacks of MOGAD. For attack prevention in children or adults, IVIG may be given as a single infusion of 1 g/kg (adjusted for ideal body weight) every three to four weeks. Some experts begin maintenance therapy with a higher initial IVIG dose (2 g/kg) followed by 1 g/kg every three to four weeks. Other options include more frequent administrations, such as 0.4 mg/kg given every week, to improve tolerance. However, most younger patients without comorbidities tolerate treatment with 1 g/kg every three to four weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Assessment of immunoglobulin A (IgA) prior to use and use of IgA-depleted
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         is recommended in those with IgA deficiency to avoid allergic reactions. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In retrospective observational studies,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         was associated with a reduction in MOGAD relapse rates [
         <a href="#rid5">
          5,9,10,13
         </a>
         ]. However, relapses can occur in up to 50 percent of patients and may be impacted by lower doses or lengthening the time interval between infusions [
         <a href="#rid13">
          13
         </a>
         ]. In one retrospective observational study, maintenance IVIG was associated with a lower risk of MOGAD relapse than other immunosuppressants (
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ), although comparisons are limited by variable doses and treatment intervals, and frequent concomitant use of oral glucocorticoids [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adverse effects of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         include headache from aseptic meningitis that can be reduced by slowing the infusion. IVIG can also increase the risk of thromboembolic events and lead to renal failure (particularly sucrose containing compounds). It is also limited by high cost. IVIG has some advantages over other medications in that it is not immunosuppressive and thus does not increase the risk of infections. (See
         <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">
          "Intravenous immune globulin: Adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Subcutaneous formulations of immunoglobulin treatments are also available but have not been well-studied in MOGAD. (See
         <a class="medical medical_review" href="/z/d/html/3942.html" rel="external">
          "Subcutaneous and intramuscular immune globulin therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rituximab
         </strong>
         –
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         is a chimeric monoclonal antibody that targets CD20 on B cells and results in B cell depletion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The traditional dose for adults is two infusions of 1000 mg (spaced two weeks apart) every six months. Other experts use an induction dose of two infusions of 1000 mg (spaced two weeks apart) followed by a lower maintenance dose of 1000 mg every six months. As an alternative,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         can be dosed at 375 mg/m
         <sup>
          2
         </sup>
         once weekly for four weeks every six months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In children,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         is generally given at a dose of 375 mg/m
         <sup>
          2
         </sup>
         by infusion once weekly for two to four weeks every six months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We generally do not recommend monitoring of B cell parameters to guide
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         dosing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         treatment has been associated with reduced annualized relapse rates in MOGAD [
         <a href="#rid5">
          5,9-11,14-16
         </a>
         ]. However, its effectiveness appears to be less than what has been observed with rituximab treatment of AQP4-IgG NMOSD, and relapses have been noted in up to 50 percent, including those with B cell depletion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adverse effects of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         include infusion reactions and increased risk of infection, including the risk of secondary hypogammaglobulinemia that may require treatment with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         . Monitoring of complete blood count and IgA, IgG, and immunoglobulin M should be performed every 6 to 12 months. Patients on rituximab should not receive live virus vaccines and may have an attenuated response to protein-based or RNA vaccines.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tocilizumab
         </strong>
         –
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          Tocilizumab
         </a>
         is an anti-interleukin-6 (IL-6) receptor monoclonal antibody, which is an important interleukin for B cell maturation and antibody production. The dose is 8 mg/kg by IV infusion every four weeks. Retrospective observational studies have included only a few patients but appear to show that tocilizumab for relapsing MOGAD is associated with a reduction in annualized relapse rates [
         <a href="#rid17">
          17,18
         </a>
         ]. Possible adverse effects include an increased risk of infection, cytopenias, and elevated liver enzymes. Regular blood monitoring is needed, including complete blood count and liver enzymes at baseline monthly for three months and every two months thereafter.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H405277033">
         <span class="h3">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The duration of attack prevention immunotherapy for patients with MOGAD is not well defined and requires further study; the decision to continue or taper immunotherapy requires careful weighing of the risks and benefits of such treatments on an individualized basis. The risk/benefit analysis of prolonged immunosuppressive strategies should be reconsidered at follow up visits, given the variable course of MOGAD.
        </p>
        <p class="headingAnchor" id="H900104734">
         <span class="h2">
          Symptomatic treatments
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiseizure medications
         </strong>
         –
         <strong>
         </strong>
         Seizures occur in up to 10 percent of patients with MOGAD and require concomitant antiseizure medications at least temporarily, but approximately 70 percent of seizures resolve within the first two weeks. In most cases, antiseizure medication can be stopped once seizures resolve. (See
         <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">
          "Seizures and epilepsy in children: Initial treatment and monitoring"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">
          "Evaluation and management of the first seizure in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – MOGAD attacks involving the brain and/or spinal cord may impair mobility and can lead to paralysis, spasticity, and incoordination that may benefit from rehabilitation treatments with involvement of physiatrists, physical therapists, and occupational therapists and additional treatments (eg,
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         for spasticity). Moreover, neurogenic bowel and bladder dysfunction are common and may require specific treatments and involvement of multidisciplinary specialists such as urologists or gastroenterologists. Erectile dysfunction may also occur and benefit from treatments. Finally, neuropathic pain and fatigue may occur and should be treated accordingly [
         <a href="#rid19">
          19,20
         </a>
         ]. The management of these complications is similar to that of multiple sclerosis. (See
         <a class="medical medical_review" href="/z/d/html/1690.html" rel="external">
          "Symptom management of multiple sclerosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1839965011">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H3801240827">
         <span class="h2">
          Risk of relapsing course
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical course of MOGAD is variable and can be divided into a monophasic or relapsing course. Persistence of the MOG antibody in some studies predicted a relapsing course when compared with those with transient seropositivity [
         <a href="#rid9">
          9,21-23
         </a>
         ]. In children, those of younger age or manifesting with ADEM were likely to have a monophasic course, while those children presenting at an older age or with optic neuritis were more likely have relapses [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">
          "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis", section on 'Clinical course: monophasic versus relapsing'
         </a>
         .)
        </p>
        <p>
         A retrospective study of 289 adults and children with MOGAD found that relapses within 12 months of onset were associated with an increased risk of relapses beyond 12 months [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H604243246">
         <span class="h2">
          Attack severity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The severity of MOGAD attacks is more akin to aquaporin-4 positive IgG (AQP4-IgG) neuromyelitis optica spectrum disorder (NMOSD) than multiple sclerosis (MS), with blindness or wheelchair dependence or severe encephalopathy or combinations thereof at the nadir of an acute attack relatively common. However, recovery with treatment is better than with AQP4-IgG NMOSD, and outcomes after attacks are more similar to MS [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3773115367">
         <span class="h2">
          Disability accrual
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disability accrues with each attack of MOGAD but is typically milder than with AQP4-IgG NMOSD. The differences in clinical course are illustrated in the figure  (
         <a class="graphic graphic_figure graphicRef131864" href="/z/d/graphic/131864.html" rel="external">
          figure 1
         </a>
         ). It appears that the initial attack may have a disproportionate impact on disability, and that an initial attack involving transverse myelitis may be a predictor of long-term disability [
         <a href="#rid27">
          27
         </a>
         ]. Subsequent attacks are often milder and associated with better recovery. The expanded disability status scale (EDSS) score is a measure of disability that was first used in patients with multiple sclerosis but has now been utilized for assessing disability in other CNS demyelinating diseases such as MOGAD. The score ranges from 0 (no disability) to 10 (death), with a score of 6 equating to the need for a gait aid and a score of 8 meaning the patient is nonambulatory  (
         <a class="graphic graphic_table graphicRef57639" href="/z/d/graphic/57639.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">
          "Clinical presentation, course, and prognosis of multiple sclerosis in adults", section on 'Disability measures'
         </a>
         .)
        </p>
        <p>
         In one study of 29 patients after a median follow-up of 14 years, the median EDSS score was 2, signifying minimal disability [
         <a href="#rid8">
          8
         </a>
         ]. An EDSS score of 6 or more, signifying need for a walking aid, was noted in only 7 percent, and blindness in one or both eyes was present in only 7 percent, but residual bowel or bladder impairment was more common at 24 percent. In another study of 61 patients with a median follow-up of 14 to 15 years, an EDSS score ≥6 occurred in 12.5 percent, and a poor visual outcome in at least one eye (visual acuity ≤0.1) occurred in 16 percent [
         <a href="#rid28">
          28
         </a>
         ]. Similarly, in another report with more patients but with shorter follow-up, sphincter and erectile dysfunction were more frequent than visual or motor disability [
         <a href="#rid27">
          27
         </a>
         ]. In this study, early immunosuppression was somewhat protective [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         However, in all these studies, there is likely a bias toward the inclusion of relapsing patients and more severe cases, which are more likely to be followed up in the long term; thus, the findings may be skewed towards worse outcomes. Future prospective studies of incident MOGAD cases with long-term follow-up are needed to determine the true prognosis with this disease.
        </p>
        <p class="headingAnchor" id="H2218078774">
         <span class="h2">
          Lack of progressive phase
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast to MS, a primary or secondary progressive course has not been associated with MOGAD in data from case series with long-term follow-up of patients [
         <a href="#rid8">
          8,27-29
         </a>
         ]. Rarely, a progressive worsening with an MRI showing a leukodystrophy-like pattern has been reported in children with MOGAD [
         <a href="#rid14">
          14,30
         </a>
         ]. Further study is needed to determine the significance of this phenotype, which differs from the progressive myelopathy, or less commonly ataxia, that typically develops in patients with progressive MS. Also, serologic analysis of 200 patients with progressive MS found no patients who were myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) positive [
         <a href="#rid31">
          31
         </a>
         ]. Rare cases of progressive MS with low-titer MOG-IgG have been reported [
         <a href="#rid32">
          32
         </a>
         ], but these are suspicious for possible false positive results. Longer follow-up of patients with true MOGAD clinic-radiologic phenotype is needed to better elucidate the risk.
        </p>
        <p class="headingAnchor" id="H605158531">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mortality rates are low in MOGAD, but severe CNS relapses may occur and can be fatal, as noted by autopsy cases among the pathologic studies of MOGAD [
         <a href="#rid33">
          33,34
         </a>
         ]. In studies with long-term follow-up of a median of 14 years, the risk of death ranged from 0 to 3 percent [
         <a href="#rid8">
          8,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1037005560">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limited data on MOGAD and pregnancy suggest a reduced risk of relapse during pregnancy but an increased risk of rebound in the early postpartum setting [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2563892545">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117065.html" rel="external">
          "Society guideline links: Multiple sclerosis and related disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H751709781">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features and diagnosis
         </strong>
         – Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory disease of the central nervous system (CNS) characterized by attacks of immune-mediated demyelination predominantly targeting the optic nerves, brain, and spinal cord. The pathogenesis, clinical features, and diagnosis of MOGAD are reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">
          "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis", section on 'Clinical course: monophasic versus relapsing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – For patients with acute attacks of MOGAD, we suggest a short course of high-dose glucocorticoid therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Our preferred regimen is intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         1000 mg per day for adults, or 20 to 30 mg/kg per day for children, for five consecutive days. An alternative for adults is oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         at the equivalent dose (described above) for five days. Observational evidence suggests that most patients with MOGAD respond briskly to glucocorticoids. (See
         <a class="local">
          'Treatment of acute attacks'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who are refractory to initial therapy with glucocorticoids, we suggest treatment with plasma exchange or intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Failure of initial acute therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We advise observation after treatment for a first attack of MOGAD, since 40 to 50 percent of patients will have no further attacks. Preventive therapy is generally reserved for patients who have relapsing disease; options include
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , intermittent
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , or
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         . However, supporting data are limited. (See
         <a class="local">
          'Relapsing disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – MOGAD may follow a monophasic or relapsing disease course. Long-term disability rates are lower than with aquaporin-4 positive IgG (AQP4-IgG) neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS)  (
         <a class="graphic graphic_figure graphicRef131864" href="/z/d/graphic/131864.html" rel="external">
          figure 1
         </a>
         ). Unlike MS, MOGAD is not associated with a primary or secondary progressive course. Mortality due to MOGAD is low. (See
         <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">
          "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis", section on 'Clinical course: monophasic versus relapsing'
         </a>
         and
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm 2019; 6:e572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu S, Liu X, Chen S, et al. Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials. PLoS One 2017; 12:e0188644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 2021; 20:762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 2018; 89:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruijstens AL, Wendel EM, Lechner C, et al. E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 2020; 29:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez-Chiriboga AS, Sechi E, Buciuc M, et al. Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder. JAMA Neurol 2020; 77:1575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hacohen Y, Wong YY, Lechner C, et al. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurol 2018; 75:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 2020; 95:e111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cobo-Calvo A, Sepúlveda M, Rollot F, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation 2019; 16:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou J, Lu X, Zhang Y, et al. Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination. Mult Scler Relat Disord 2019; 28:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen JJ, Huda S, Hacohen Y, et al. Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurol 2022; 79:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armangue T, Olivé-Cirera G, Martínez-Hernandez E, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol 2020; 19:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durozard P, Rico A, Boutiere C, et al. Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases. Ann Neurol 2020; 87:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai P, Zhang M, Yuan J, et al. A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: A meta-analysis. Mult Scler Relat Disord 2021; 53:103044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elsbernd PM, Hoffman WR, Carter JL, Wingerchuk DM. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review. Mult Scler Relat Disord 2021; 48:102696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rigal J, Pugnet G, Ciron J, et al. Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: A case-series. Mult Scler Relat Disord 2020; 46:102483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ladakis DC, Gould J, Khazen JM, et al. Fatigue is a common symptom in myelin oligodendrocyte glycoprotein antibody disease. Mult Scler J Exp Transl Clin 2022; 8:20552173221131235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asseyer S, Henke E, Trebst C, et al. Pain, depression, and quality of life in adults with MOG-antibody-associated disease. Eur J Neurol 2021; 28:1645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waters P, Fadda G, Woodhall M, et al. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurol 2020; 77:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hennes EM, Baumann M, Schanda K, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 2017; 89:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. JAMA Neurol 2018; 75:1355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fadda G, Armangue T, Hacohen Y, et al. Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. Lancet Neurol 2021; 20:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen B, Gomez-Figueroa E, Redenbaugh V, et al. Do Early Relapses Predict the Risk of Long-Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD? Ann Neurol 2023; 94:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jitprapaikulsan J, Chen JJ, Flanagan EP, et al. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. Ophthalmology 2018; 125:1628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 2017; 140:3128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deschamps R, Pique J, Ayrignac X, et al. The long-term outcome of MOGAD: An observational national cohort study of 61 patients. Eur J Neurol 2021; 28:1659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akaishi T, Misu T, Takahashi T, et al. Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders. J Neuroimmunol 2021; 351:577467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hacohen Y, Rossor T, Mankad K, et al. 'Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease. Dev Med Child Neurol 2018; 60:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarius S, Ruprecht K, Stellmann JP, et al. MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. J Neuroinflammation 2018; 15:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcucci SB, Elkasaby M, Walch R, et al. Progressive myelopathy in myelin oligodendrocyte glycoprotein antibody-associated disease: A new mimicker of progressive multiple sclerosis? Mult Scler Relat Disord 2021; 52:102964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Höftberger R, Guo Y, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol 2020; 139:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takai Y, Misu T, Kaneko K, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain 2020; 143:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collongues N, Alves Do Rego C, Bourre B, et al. Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder. Neurology 2021; 96:e2006.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 132021 Version 6.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31355308" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29176905" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34418402" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Myelin-oligodendrocyte glycoprotein antibody-associated disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27793206" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29142145" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10589540" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33176999" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32865549" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29305608" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32554760" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31266527" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30529926" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35377395" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32057303" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31725931" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34091176" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33360264" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32942119" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: A case-series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36407471" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Fatigue is a common symptom in myelin oligodendrocyte glycoprotein antibody disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33423336" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Pain, depression, and quality of life in adults with MOG-antibody-associated disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31545352" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28768844" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30014148" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33484648" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37394961" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Do Early Relapses Predict the Risk of Long-Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29716788" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29136091" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical presentation and prognosis in MOG-antibody disease: a UK study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33528851" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The long-term outcome of MOGAD: An observational national cohort study of 61 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33388541" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29288492" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : 'Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29554927" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33915519" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Progressive myelopathy in myelin oligodendrocyte glycoprotein antibody-associated disease: A new mimicker of progressive multiple sclerosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32048003" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32412053" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33627499" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
